| CAS NO: | 1185879-03-1 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| Cas No. | 1185879-03-1 |
| 别名 | 己酮可可碱 d6 |
| Canonical SMILES | O=C1C2=C(N=CN2C([2H])([2H])[2H])N(C(N1CCCCC(C)=O)=O)C([2H])([2H])[2H] |
| 分子式 | C13H12D6N4O3 |
| 分子量 | 284.3 |
| 溶解度 | Acetonitrile: soluble,DMSO: soluble,Methanol: soluble |
| 储存条件 | -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Pentoxifylline-d6is intended for use as an internal standard for the quantification of pentoxifylline by GC- or LC-MS. Pentoxifylline is a hemorrheologic agent.1It increases the deformability of washed isolated human erythrocytes when used at a concentration of 100 µM.2Pentoxifylline (1, 2, and 3 mM) inhibits ADP-induced platelet aggregation in isolated human whole blood.3It inhibits thrombus formation induced by ADP in a hamster cheek pouch model when administered at doses of 5, 10, and 20 mg/kg.4Formulations containing pentoxifylline have been used in the treatment of intermittent claudication. 1.Ward, A., and Clissold, S.P.Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacyDrugs34(1)50-97(1987) 2.S?oczyńska, K., KÓzka, M., P?kala, E., et al.In vitro effect of pentoxifylline and lisofylline on deformability and aggregation of red blood cells from healthy subjects and patients with chronic venous diseaseActa Biochim. Pol.60(1)129-135(2013) 3.Magnusson, B., Gunnarsson, M., Berntorp, E., et al.Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humansEur. J. Pharmacol.581(3)290-295(2008) 4.Michal, M., Giessinger, N., and SchrÖer, R.Reduced thrombus formation in vivo after administration of pentoxifylline (Trental)Thromb. Res.56(3)359-368(1989) |
m.cnreagent.com